

Press Release  
Lund, May 3, 2016

## Enzymatica insiders plan to subscribe for SEK 16 million in new issue

**Enzymatica announces that insiders such as board members, senior executives and their family members plan to subscribe for shares in the ongoing new issue equivalent to an amount of at least SEK 16 million, which corresponds to 27 percent of the issue. The rights issue is set to raise approximately SEK 60 million for the company before issue expenses. The rights issue is 100% underwritten via subscription and underwriting commitments.**

As previously announced by the company, the main terms and conditions of the rights issue are as follows:

The company's shareholders will have preemptive rights to subscribe for the new shares in proportion to the number of shares they previously held. One (1) subscription right will be received for each existing share. Five (5) subscription rights entitle the holder to subscribe for three (3) new shares. The subscription price will be SEK 2.18 for each new share. For more information, please see <http://enzymatica.com/investors/nyemission-april-2016>

Schedule:

April 21–May 3	Trading in subscription rights
April 21–May 6	Subscription period
May 11	Estimated date of publication of rights issue outcome

The proceeds of the rights issue will be used to finance the company's geographic expansion, cover the costs of product development, including clinical studies and product documentation, and conduct its operating activities.

### For more information, contact:

---

Fredrik Lindberg, CEO Enzymatica AB  
Tel: +46 (0)708-86 53 70 | Email: [fredrik.lindberg@enzymatica.com](mailto:fredrik.lindberg@enzymatica.com)

### About Enzymatica AB

Enzymatica AB is a life sciences company that develops and sells medical devices for fighting infectious diseases. In a short period of time, the company developed ColdZyme®, a unique mouth spray for fighting colds, launched the product in six markets and established it as one of the best-selling cold products in Swedish pharmacies measured in SEK. Our strategy is to continue growing by strengthening our position on existing markets and expanding to more geographic markets via established partners. The company's head office is in Lund and it is listed on the Nasdaq First North. For more information, please go to: [www.enzymatica.se](http://www.enzymatica.se).

Enzymatica's certified advisor is Erik Penser Bankaktiebolag.